454 related articles for article (PubMed ID: 28169360)
1. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
[TBL] [Abstract][Full Text] [Related]
2. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
3. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
4. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.
Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA
J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985
[TBL] [Abstract][Full Text] [Related]
5. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
6. Effects of the hippo signaling pathway in human gastric cancer.
Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB
Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801
[TBL] [Abstract][Full Text] [Related]
7. DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1/2.
Kwan J; Sczaniecka A; Heidary Arash E; Nguyen L; Chen CC; Ratkovic S; Klezovitch O; Attisano L; McNeill H; Emili A; Vasioukhin V
Genes Dev; 2016 Dec; 30(24):2696-2709. PubMed ID: 28087714
[TBL] [Abstract][Full Text] [Related]
8. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
10. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
11. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
12. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
13. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
14. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
15. LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.
Shi Y; Geng D; Zhang Y; Zhao M; Wang Y; Jiang Y; Yu R; Zhou X
J Mol Neurosci; 2019 May; 68(1):38-48. PubMed ID: 30771084
[TBL] [Abstract][Full Text] [Related]
16. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis.
Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820
[TBL] [Abstract][Full Text] [Related]
17. Hippo kinases regulate cell junctions to inhibit tumor metastasis in response to oxidative stress.
Wang Y; Li J; Gao Y; Luo Y; Luo H; Wang L; Yi Y; Yuan Z; Jim Xiao ZX
Redox Biol; 2019 Sep; 26():101233. PubMed ID: 31212215
[TBL] [Abstract][Full Text] [Related]
18. A Ca
Dang DK; Makena MR; Llongueras JP; Prasad H; Ko M; Bandral M; Rao R
Mol Cancer Res; 2019 Aug; 17(8):1735-1747. PubMed ID: 31076498
[TBL] [Abstract][Full Text] [Related]
19. The peptide mimicking small extracellular ring domain of CD82 inhibits epithelial-mesenchymal transition by downregulating Wnt pathway and upregulating hippo pathway.
He X; Huang X; Wang C; Luan M; Li Y; Ma X; Ma K
Biochem Biophys Res Commun; 2020 Dec; 533(3):338-345. PubMed ID: 32958256
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]